Announcement • Mar 31
Bioventix PLC Confirms Interim Dividend for the Six Months Ended 31 December 2025, Payable on 24 April 2026 The Board of Bioventix PLC confirmed an interim dividend for the six months ended 31 December 2025 of 70 pence per share (2024: 70 pence per share). The shares will be marked ex-dividend on the 9 April 2026 and the dividend will be paid on 24 April 2026 to shareholders on the register at close of business on 10 April 2026. Announcement • Feb 25
BioVentix PLC Announces Appointment Of Chris Yates As Independent Non-Executive Director, Effective March 1, 2026 BioVentix PLC announced the appointment of Chris Yates as independent Non-Executive Director, effective March 1, 2026. Chris Yates brings extensive board-level and sector expertise, underpinned by over 20 years' experience operating within publicly listed company environments. Over the past decade, Chris has led the development and growth of Abingdon Health plc. Chris co-founded the business in 2008, initially serving as Non-Executive Director and then in 2015 becoming Chief Executive Officer until 2025 when he was appointed President of Abingdon Health USA and Group Chief Commercial Officer. Chris also serves as a Non-Executive Director and Chairman of the Audit Committee of AIM-listed Genedrive plc. Earlier in his career, Chris was CFO of AIM-listed companies Immunodiagnostic Systems Holdings PLC and Cozart plc. Chris is a Chartered Accountant and has a degree in economics from the University of Cambridge. Chris Yates, aged 51, holds current directorships and/or partnerships at Abingdon Analytical Limited, Compliance Solutions (Life Sciences) Limited, IVDeology Holdings Limited, IVDeology Limited, IVDeology UKRP Limited, Molecular Vision Limited, Genedrive plc, Foresite Diagnostics Limited, Find Out from Home Inc., and Abingdon Health USA Inc. Past directorships and/or partnerships (within the last five years) include Abingdon Health plc and Serascience Limited. Announcement • Nov 11
Bioventix PLC, Annual General Meeting, Dec 04, 2025 Bioventix PLC, Annual General Meeting, Dec 04, 2025. Location: farnham castle, farnham, surrey, gu9 0ag, United Kingdom Announcement • Mar 31
Bioventix PLC Announces Interim Dividend, Payable on April 25, 2025 The Board of Bioventix PLC announced an interim dividend of 70 pence per share which represents a 3% increase on the interim dividend paid last year (68 pence per share). The shares will be marked ex-dividend on the 10th April 2025 and the dividend will be paid on 25th April 2025 to shareholders on the register at close of business on 11th April 2025. Announcement • Nov 09
Bioventix PLC, Annual General Meeting, Dec 05, 2024 Bioventix PLC, Annual General Meeting, Dec 05, 2024. Location: farnham castle, surrey, gu9 0ag, farnham United Kingdom Declared Dividend • Oct 30
Final dividend of UK£0.87 announced Shareholders will receive a dividend of UK£0.87. Ex-date: 7th November 2024 Payment date: 21st November 2024 Dividend yield will be 4.4%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not adequately covered by cash flows (95% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to remain steady over the next year, which should provide adequate earnings cover for the dividend. Reported Earnings • Oct 30
Full year 2024 earnings released: EPS: UK£1.55 (vs UK£1.61 in FY 2023) Full year 2024 results: EPS: UK£1.55 (down from UK£1.61 in FY 2023). Revenue: UK£13.6m (up 6.2% from FY 2023). Net income: UK£8.10m (down 3.3% from FY 2023). Profit margin: 60% (down from 65% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Oct 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Declared Dividend • Mar 27
First half dividend of UK£0.68 announced Shareholders will receive a dividend of UK£0.68. Ex-date: 11th April 2024 Payment date: 26th April 2024 Dividend yield will be 3.3%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it adequately covered by cash flows (99% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. EPS is expected to grow by 5.1% over the next year, which should be enough to bring the dividend into a sustainable range. Reported Earnings • Mar 26
First half 2024 earnings released: EPS: UK£0.77 (vs UK£0.72 in 1H 2023) First half 2024 results: EPS: UK£0.77 (up from UK£0.72 in 1H 2023). Revenue: UK£6.68m (up 13% from 1H 2023). Net income: UK£4.02m (up 7.9% from 1H 2023). Profit margin: 60% (down from 63% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 22
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 32% to €58.50. The fair value is estimated to be €48.64, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years. Earnings per share has grown by 7.6%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 12% in the next 2 years. Announcement • Nov 13
Bioventix PLC, Annual General Meeting, Dec 07, 2023 Bioventix PLC, Annual General Meeting, Dec 07, 2023, at 14:00 Coordinated Universal Time. Location: Farnham Castle, Farnham Surrey United Kingdom Announcement • Oct 31
Bioventix PLC Announces Second Interim Dividend, Payable on 24 November 2023 Bioventix PLC announced a second interim dividend of 90 pence per share which, when added to the first interim dividend of 62 pence per share makes a total of 152 pence per share for the current year. Accordingly, a dividend of 90 pence per share will be paid in November 2023. The shares will be marked ex-dividend on 9 November 2023 and the dividend will be paid on 24 November 2023 to shareholders on the register at close of business on 10 November 2023. Reported Earnings • Oct 31
Full year 2023 earnings released: EPS: UK£1.61 (vs UK£1.47 in FY 2022) Full year 2023 results: EPS: UK£1.61 (up from UK£1.47 in FY 2022). Revenue: UK£12.8m (up 9.4% from FY 2022). Net income: UK£8.37m (up 9.1% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. New Risk • Oct 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • May 31
Bioventix plc Appoints Joanne (Jo) Pisani to the Board as an Independent Non-Executive Director Bioventix plc announced that it has appointed Joanne (Jo) Pisani to the Board, as an independent Non-Executive Director, with immediate effect. Jo will chair the Company's Audit Committee. Jo is a chartered engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK and BP in strategy, commercial and operational functions before working in strategic consultancy. She led PwC's UK Pharmaceutical and Life Sciences practice, assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions. Recent Insider Transactions • Apr 03
Independent Non-Executive Chairman recently sold €111k worth of stock On the 31st of March, Ian Nicholson sold around 3k shares on-market at roughly €44.41 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €2.4m. This was Ian's only on-market trade for the last 12 months. Upcoming Dividend • Mar 30
Upcoming dividend of UK£0.62 per share at 3.9% yield Eligible shareholders must have bought the stock before 06 April 2023. Payment date: 21 April 2023. Payout ratio and cash payout ratio are on the higher end at 84% and 99% respectively. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (2.5%). Reported Earnings • Mar 28
First half 2023 earnings released: EPS: UK£0.72 (vs UK£0.57 in 1H 2022) First half 2023 results: EPS: UK£0.72 (up from UK£0.57 in 1H 2022). Revenue: UK£5.90m (up 25% from 1H 2022). Net income: UK£3.73m (up 25% from 1H 2022). Profit margin: 63% (in line with 1H 2022). Revenue is forecast to grow 5.6% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year. Recent Insider Transactions • Feb 03
CEO & Director recently sold €2.4m worth of stock On the 31st of January, Peter Harrison sold around 58k shares on-market at roughly €42.53 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months. Announcement • Nov 09
Bioventix PLC, Annual General Meeting, Dec 08, 2022 Bioventix PLC, Annual General Meeting, Dec 08, 2022, at 14:00 Coordinated Universal Time. Location: Farnham Castle, Farnham, Surrey United Kingdom Upcoming Dividend • Oct 27
Upcoming dividend of UK£1.00 per share Eligible shareholders must have bought the stock before 03 November 2022. Payment date: 18 November 2022. Payout ratio is on the higher end at 86%, and the cash payout ratio is above 100%. Trailing yield: 4.5%. Lower than top quartile of German dividend payers (5.0%). Higher than average of industry peers (2.2%). Reported Earnings • Oct 25
Full year 2022 earnings released: EPS: UK£1.47 (vs UK£1.29 in FY 2021) Full year 2022 results: EPS: UK£1.47 (up from UK£1.29 in FY 2021). Revenue: UK£11.7m (up 7.2% from FY 2021). Net income: UK£7.67m (up 14% from FY 2021). Profit margin: 66% (up from 62% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat. Announcement • Sep 14
Bioventix PLC to Report Fiscal Year 2022 Results on Oct 24, 2022 Bioventix PLC announced that they will report fiscal year 2022 results on Oct 24, 2022 Upcoming Dividend • Mar 31
Upcoming dividend of UK£0.52 per share Eligible shareholders must have bought the stock before 07 April 2022. Payment date: 22 April 2022. Payout ratio is on the higher end at 83%, and the cash payout ratio is above 100%. Trailing yield: 4.4%. Within top quartile of German dividend payers (3.7%). Higher than average of industry peers (1.4%). Reported Earnings • Mar 30
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£3.10m from profit in 1H 2021). Profit margin: (down from 60% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 2.4%, compared to a 88% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Mar 28
Bioventix PLC Announces First Interim Dividend, Payable on 22 April 2021 Bioventix PLC announced first interim dividend of 52 pence per share which represents a 20% increase on the interim dividend paid last year (43 pence per share). The shares will be marked ex-dividend on the 7 April 2021 and the dividend will be paid on 22 April 2021 to shareholders on the register at close of business on 8 April 2021. Upcoming Dividend • Oct 21
Upcoming dividend of UK£1.00 per share Eligible shareholders must have bought the stock before 28 October 2021. Payment date: 12 November 2021. Trailing yield: 3.9%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.0%). Reported Earnings • Oct 19
Full year 2021 earnings released: EPS UK£1.29 (vs UK£1.39 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£10.9m (up 6.0% from FY 2020). Net income: UK£6.73m (down 6.5% from FY 2020). Profit margin: 62% (down from 70% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 01
First half 2021 earnings released: EPS UK£0.59 (vs UK£0.67 in 1H 2020) The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£5.16m (up 1.3% from 1H 2020). Net income: UK£3.10m (down 9.6% from 1H 2020). Profit margin: 60% (down from 67% in 1H 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 21
New 90-day high: €49.80 The company is up 8.0% from its price of €46.00 on 23 October 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: €48.10 The company is up 10.0% from its price of €43.80 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period. Reported Earnings • Nov 19
Full year 2020 earnings released: EPS UK£1.39 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£10.3m (up 11% from FY 2019). Net income: UK£7.20m (up 23% from FY 2019). Profit margin: 70% (up from 63% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Nov 19
Revenue beats expectations Revenue exceeded analyst estimates by 2.1%. Announcement • Nov 17
Bioventix PLC, Annual General Meeting, Dec 10, 2020 Bioventix PLC, Annual General Meeting, Dec 10, 2020, at 14:00 Coordinated Universal Time. Upcoming Dividend • Oct 22
Upcoming Dividend of UK£1.05 Per Share Will be paid on the 13th of November to those who are registered shareholders by the 29th of October. The trailing yield of 3.4% is below the top quartile of German dividend payers (3.8%), but it is higher than industry peers (1.1%). Analyst Estimate Surprise Post Earnings • Oct 19
Annual earnings released: Revenue beats expectations Annual revenue exceeded analyst estimates by 2.1% at UK£10.3m. Reported Earnings • Oct 19
Full year earnings released - EPS €1.39 Over the last 12 months the company has reported total profits of UK£7.20m, up 23% from the prior year. Total revenue was UK£10.3m over the last 12 months, up 11% from the prior year. Profit margins were 70%, which is higher than the 63% margin from last year. The increase in margin was primarily driven by higher revenue. Announcement • Oct 19
Bioventix plc Announces Treena Turner Steps Down from the Board Bioventix PLC announced that Treena Turner, non-executive finance director, has stepped down from the Board. Announcement • Sep 19
Bioventix to Be Deleted from Other OTC Bioventix PLC’s ESHER Ordinary Shares (United Kingdom) will be deleted from Other OTC effective September 21, 2020. The deletion was due to Inactive Security.